Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Total Liabilities (2022 - 2025)

Historic Total Liabilities for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $62.9 million.

  • Day One Biopharmaceuticals' Total Liabilities rose 3874.38% to $62.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.9 million, marking a year-over-year increase of 3874.38%. This contributed to the annual value of $80.0 million for FY2024, which is 17123.83% up from last year.
  • Day One Biopharmaceuticals' Total Liabilities amounted to $62.9 million in Q3 2025, which was up 3874.38% from $58.2 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Total Liabilities' 5-year high stood at $93.7 million during Q2 2024, with a 5-year trough of $8.2 million in Q1 2022.
  • Over the past 4 years, Day One Biopharmaceuticals' median Total Liabilities value was $29.5 million (recorded in 2023), while the average stood at $38.9 million.
  • In the last 5 years, Day One Biopharmaceuticals' Total Liabilities soared by 27934.58% in 2024 and then plummeted by 3788.76% in 2025.
  • Over the past 4 years, Day One Biopharmaceuticals' Total Liabilities (Quarter) stood at $17.0 million in 2022, then soared by 73.34% to $29.5 million in 2023, then surged by 171.24% to $80.0 million in 2024, then dropped by 21.4% to $62.9 million in 2025.
  • Its last three reported values are $62.9 million in Q3 2025, $58.2 million for Q2 2025, and $54.8 million during Q1 2025.